Elevated tumor expression of PAI-1 and SNAI2 in obese esophageal adenocarcinoma patients and impact on prognosis

Clinical and Translational Gastroenterology

Volumn 3, Issue , 2012, Pages

  Allott, Emma H ^a   Morine, Melissa J ^b,c   Lysaght, Joanne ^a   McGarrigle, Sarah A ^a   Donohoe, Claire L ^a   Reynolds, John V ^a   Roche, Helen M ^b   Pidgeon, Graham P ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF TRENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ALPHA3 INTEGRIN; ALPHA6 INTEGRIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRUCTOSE BISPHOSPHATE ALDOLASE; HEXOKINASE 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; LACTATE DEHYDROGENASE; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 3; ONCOSTATIN M RECEPTOR; OSTEOPONTIN; PAXILLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVATE KINASE; SERINE PROTEINASE INHIBITOR; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR INVASION;

EID: 84878830619     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.5     Document Type: Article

References (48)

1. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
2. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
3. National Cancer Registry, Ireland. Incidence, Mortality, Treatment and Survival 1994-2007, http://www.ncri.ie/data.cgi/choose-methods.php.
4. Engel LS, Chow WH, Vaughan TL. et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-1413.
5. Lagarde SM, ten Kate FJ, Richel DJ et al. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007; 14: 977-991.
6. Kjoller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
7. Brooks TD, Slomp J, Quax PH et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis 2000; 18: 445-453.
8. Moreno-Bueno G, Cubillo E, Sarrio D et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 2006; 66: 9543-9556.
9. Freytag J, Wilkins-Port CE, Higgins CE et al. PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes. J Invest Dermatol 2010; 130: 2179-2190.
10. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-e91.
11. Alves CC, Carneiro F, Hoefler H et al. Role of the epithelial-mesenchymal transition regulator slug in primary human cancers. Front Biosci 2009; 14: 3035-3050.
12. Perez-Mancera PA, Bermejo-Rodriguez C, Gonzalez-Herrero I et al. Adipose tissue mass is modulated by SLUG (SNAI2). Hum Mol Genet 2007; 16: 2972-2986.
13. The International Diabetes Federation. The IDF Consensus: Worldwide Definition of the Metabolic Syndrome 2006. http://www.idf.org/webdata/docs/MetS- def-update2006.pdf.
14. Despres JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993; 6: 137-159.
15. Lemieux S, Prud'homme D, Bouchard C. et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64: 685-693.
16. Lysaght J, Allott EH, Donohoe CL et al. T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 2011; 98: 964-974.
17. Ennis DP, Pidgeon GP, Millar N et al. Building a bioresource for esophageal research: lessons from the early experience of an academic medical center. Dis Esophagus 2010; 23: 1-7.
18. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 2001; 155: 197-212.
19. Zhang HH, Kumar S, Barnett AH et al. Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. J Endocrinol 2000; 164: 119-128.
20. Parman C, Halling C, Gentleman R. affyQCReport: QC Report Generation for affyBatch objects. R package.
21. Wu Z, Irizarry RA, Gentleman R et al. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004; 99: 909-917.
22. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1-25.
23. Jiang Z, Gentleman R. Extensions to gene set enrichment. Bioinformatics 2007; 23: 306-313.
24. Morine MJ, McMonagle J, Toomey S et al. Bi-directional gene set enrichment and canonical correlation analysis identify key diet-sensitive pathways and biomarkers of metabolic syndrome. BMC Bioinformatics 2010; 11: 499.
25. Skvortsov S, Schafer G, Stasyk T et al. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies lamin A as a discriminatory biomarker. J Proteome Res 2011; 10: 259-268.
26. Kellenberger LD, Bruin JE, Greenaway J et al. The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol 2010; 2010: 514310.
27. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
28. Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 2008; 454: 436-444.
29. Chavey C, Lazennec G, Lagarrigue S et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 2009; 9: 339-349.
30. Iliopoulos D, Malizos KN, Oikonomou P et al. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008; 3: e3740.
31. Bianchi A, Gervasi ME, Bakin AV. Role of beta5-integrin in epithelial-mesenchymal transition in response to TGFbeta. Cell Cycle 2010; 9: 1647-1659.
32. Onwuegbusi BA, Rees JR, Lao-Sirieix P et al. Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One 2007; 2: e177.
33. Ma LJ, Mao SL, Taylor KL et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.
34. Sternlicht MD, Dunning AM, Moore DH et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006; 15: 2107-2114.
35. Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004; 5: 348-352.
36. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-2907.
37. Langenskiold M, Holmdahl L, Angenete E et al. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009; 30: 210-220.
38. Angenete E, Langenskiold M, Palmgren I et al. uPA and PAI-1 in rectal cancer - relationship to radiotherapy and clinical outcome. J Surg Res 2009; 153: 46-53.
39. Sakakibara T, Hibi K, Koike M et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005; 93: 799-803.
40. Come C, Magnino F, Bibeau F et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006; 12: 5395-5402.
41. Martin TA, Goyal A, Watkins G et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12: 488-496.
42. Kumar A, Chatopadhyay T, Raziuddin M et al. Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer 2007; 120: 230-242.
43. Shioiri M, Shida T, Koda K et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006; 94: 1816-1822.
44. Jethwa P, Naqvi M, Hardy RG et al. Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol 2008; 14: 1044-1052.
45. Zhang K, Zhang S, Jiao X et al. Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo. Med Oncol 2011; 28: 1089-1100.
46. Allott EH, Lysaght J, Cathcart MC et al. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation. Mol Carcinog 2011; doi: 10.1002/mc.21840.
47. Uchikado Y, Natsugoe S, Okumura H et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 1174-1180.
48. Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010; 4: 315-324.